OnKure (OKUR) grants CMO 110,000 stock options at $4.07 strike

Rhea-AI Filing Summary

OnKure Therapeutics, Inc. Chief Medical Officer Samuel Agresta reported a compensation-related grant of 110,000 employee stock options to buy Class A Common Stock. The options carry an exercise price of $4.07 per share and expire on March 31, 2036.

According to the filing, 1/48th of the options will vest on May 1, 2026 and then monthly thereafter, as long as he continues as a service provider. Following this grant, he holds 110,000 derivative securities directly, with no open-market buying or selling reported.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Agresta Samuel

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	110,000	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 110,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 110,000 options Exercise price: $4.07 per share Expiration date: March 31, 2036 +1 more

4 metrics

Option grant size 110,000 options Employee stock option grant reported on April 1, 2026

Exercise price $4.07 per share Exercise price for Class A Common Stock under options

Expiration date March 31, 2036 Option expiration for granted employee stock options

Post-grant derivative holdings 110,000 derivative securities Total options held directly after the grant

Key Terms

Employee Stock Option, Class A Common Stock, exercise price, vesting

4 terms

Employee Stock Option financial

"Employee Stock Option (right to buy)"

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

Class A Common Stock financial

"underlying security title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

exercise price financial

"conversion or exercise price of 4.0700 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"1/48th of the shares subject to the option shall vest on May 1, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Agresta Samuel

(Last) (First) (Middle)

C/O ONKURE THERAPEUTICS, INC.

6707 WINCHESTER CIRCLE, SUITE 400

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$4.07	04/01/2026		A		110,000		(1)	03/31/2036	Class A Common Stock	110,000	$0	110,000	D

Explanation of Responses:

1. 1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

	/s/ Rogan Nunn, by power of attorney	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did OnKure Therapeutics (OKUR) disclose in this Form 4 for Samuel Agresta?

OnKure Therapeutics reported a grant of 110,000 employee stock options to Chief Medical Officer Samuel Agresta. These options are compensation, not an open-market trade, and give him the right to buy Class A Common Stock at a fixed exercise price.

How many OnKure (OKUR) stock options were granted and at what exercise price?

Samuel Agresta received 110,000 employee stock options for OnKure Class A Common Stock. The options have an exercise price of $4.07 per share, meaning he can buy the shares at that price once the options vest and are exercisable.

When do Samuel Agresta’s OnKure (OKUR) options vest under this Form 4 filing?

The filing states that 1/48th of the option shares will vest on May 1, 2026, with additional 1/48th portions vesting each month thereafter. Vesting is contingent on Samuel Agresta continuing as a service provider through each applicable vesting date.

Are the OnKure (OKUR) option grants to Samuel Agresta an open-market purchase or compensation?

The transaction is a compensation-related grant, not an open-market purchase. The Form 4 uses transaction code “A” for a grant or award acquisition, reflecting employee stock options awarded to the Chief Medical Officer at a $4.07 exercise price.

When do Samuel Agresta’s OnKure (OKUR) stock options expire?

The employee stock options granted to Samuel Agresta expire on March 31, 2036. He can exercise vested options any time before that expiration date, subject to the company’s equity plan terms and his continued service-based vesting conditions.

How many derivative securities does Samuel Agresta hold in OnKure (OKUR) after this grant?

After the reported grant, Samuel Agresta holds 110,000 derivative securities related to OnKure Class A Common Stock. These consist entirely of the newly granted employee stock options reported in this Form 4, held as direct ownership.